File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma

TitleEvaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma
Authors
KeywordsChinese
Early antigen
Epstein-Barr virus
Nasopharyngeal carcinoma
Virus capsid antigen
Issue Date2007
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcv
Citation
Journal Of Clinical Virology, 2007, v. 40 n. 4, p. 284-288 How to Cite?
AbstractBackground: Immunofluorescence (IF) assays based on Epstein-Barr virus (EBV)-encoded antigens have traditionally been the preferred approach for serological screening of nasopharyngeal carcinoma (NPC). Objectives: To compare the performance of two new commercial assays (indicated by COMM) using, respectively, the IF and enzyme-linked immunosorbent assay (ELISA) formats with an in-house IF assay (IFA). Study design: Sera from 163 patients with histologically confirmed NPC, and 98 healthy controls were tested with each of these assays and their results compared. Results: The sensitivity, specificity, positive and negative predictive values, respectively, for the COMM VCA IgA ELISA were 92.6%, 94.9%, 96.8%, 88.6%; for the COMM VCA IgA IFA were 96.9%, 41.8%, 73.5%, 89.1%; for the in-house VCA IgA IFA were 98.2%, 72.4%, 85.6%, 95.9%; for the COMM EA IgA ELISA were 46.6%, 100%, 100%, 53.0%; for the COMM EA IgA IFA were 77.3%, 100%, 100%, 72.6%; and for the in-house EA IgA IFA were 77.9%, 99.0%, 99.2%, 72.9%. Conclusions: The receiver operating characteristic curves comparison showed a marginal superior accuracy for the COMM VCA IgA ELISA, suggesting this to be used as a high-throughput serological screening assay, with the more specific COMM EA IgA IFA as a follow-up confirmatory assay in this NPC-endemic area. © 2007 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/92061
ISSN
2015 Impact Factor: 2.647
2015 SCImago Journal Rankings: 1.503
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, JWen_HK
dc.contributor.authorRohwäder, Een_HK
dc.contributor.authorChu, IMTen_HK
dc.contributor.authorTsang, RKYen_HK
dc.contributor.authorSteinhagen, Ken_HK
dc.contributor.authorYeung, ACMen_HK
dc.contributor.authorTo, KFen_HK
dc.contributor.authorChan, PKSen_HK
dc.date.accessioned2010-09-17T10:34:56Z-
dc.date.available2010-09-17T10:34:56Z-
dc.date.issued2007en_HK
dc.identifier.citationJournal Of Clinical Virology, 2007, v. 40 n. 4, p. 284-288en_HK
dc.identifier.issn1386-6532en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92061-
dc.description.abstractBackground: Immunofluorescence (IF) assays based on Epstein-Barr virus (EBV)-encoded antigens have traditionally been the preferred approach for serological screening of nasopharyngeal carcinoma (NPC). Objectives: To compare the performance of two new commercial assays (indicated by COMM) using, respectively, the IF and enzyme-linked immunosorbent assay (ELISA) formats with an in-house IF assay (IFA). Study design: Sera from 163 patients with histologically confirmed NPC, and 98 healthy controls were tested with each of these assays and their results compared. Results: The sensitivity, specificity, positive and negative predictive values, respectively, for the COMM VCA IgA ELISA were 92.6%, 94.9%, 96.8%, 88.6%; for the COMM VCA IgA IFA were 96.9%, 41.8%, 73.5%, 89.1%; for the in-house VCA IgA IFA were 98.2%, 72.4%, 85.6%, 95.9%; for the COMM EA IgA ELISA were 46.6%, 100%, 100%, 53.0%; for the COMM EA IgA IFA were 77.3%, 100%, 100%, 72.6%; and for the in-house EA IgA IFA were 77.9%, 99.0%, 99.2%, 72.9%. Conclusions: The receiver operating characteristic curves comparison showed a marginal superior accuracy for the COMM VCA IgA ELISA, suggesting this to be used as a high-throughput serological screening assay, with the more specific COMM EA IgA IFA as a follow-up confirmatory assay in this NPC-endemic area. © 2007 Elsevier B.V. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcven_HK
dc.relation.ispartofJournal of Clinical Virologyen_HK
dc.subjectChineseen_HK
dc.subjectEarly antigenen_HK
dc.subjectEpstein-Barr virusen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectVirus capsid antigenen_HK
dc.titleEvaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailTsang, RKY: rkytsang@hku.hken_HK
dc.identifier.authorityTsang, RKY=rp01386en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jcv.2007.09.006en_HK
dc.identifier.pmid17977062-
dc.identifier.scopuseid_2-s2.0-36348982127en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-36348982127&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume40en_HK
dc.identifier.issue4en_HK
dc.identifier.spage284en_HK
dc.identifier.epage288en_HK
dc.identifier.isiWOS:000252103400003-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridTang, JW=10341387300en_HK
dc.identifier.scopusauthoridRohwäder, E=6504464796en_HK
dc.identifier.scopusauthoridChu, IMT=7103327448en_HK
dc.identifier.scopusauthoridTsang, RKY=7102940058en_HK
dc.identifier.scopusauthoridSteinhagen, K=23010764600en_HK
dc.identifier.scopusauthoridYeung, ACM=21234619400en_HK
dc.identifier.scopusauthoridTo, KF=7101911940en_HK
dc.identifier.scopusauthoridChan, PKS=32067487100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats